Education
About Us
Working with TipRanks
Follow Us
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
ABVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.50 - $17.02
Previous CloseN/A
Volume62.24K
Average Volume (3M)139.20K
Market Cap
$456.45M
Enterprise ValueN/A
Total Cash (Recent Filing)€9.77M
Total Debt (Recent Filing)€20.74M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Mar 24, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding63,383,293
10 Day Avg. Volume116,158
30 Day Avg. Volume139,204
Standard Deviation0.12
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)83.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.50Price Target Upside323.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Abivax SA Sponsored ADR News
PremiumCompany Announcements
Abivax Initiates $150 Million ATM Program on Nasdaq
PremiumCompany Announcements
Abivax Reports Strong Q3 Financials and Clinical Progress
PremiumCompany Announcements
Abivax SA Unveils New Ulcerative Colitis Treatment Data
PremiumCompany Announcements
Abivax Reports Progress in Ulcerative Colitis Therapy
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAbivax announced it has exceeded 80% of planned enrollment in the two Phase 3 induction trials evaluating obefazimod in patients with ulcerative colitis.
Financial StabilityThe company reiterated that its current cash is sufficient to fund operations into 4Q25, beyond the readout of the Phase 3 induction results.
Bears Say
Timeline DelaysThe timeline for the Phase 3 trial of obefazimod in ulcerative colitis has been pushed back, with topline data now expected later than previously guided.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.80% Mutual Funds
38.34% Other Institutional Investors
60.87% Public Companies and Individual Investors
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $5.50 and its highest was $17.02 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $456.45M.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Mar 24, 2025 which is in 21 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on Nov 07, 2024. The company reported -$0.696 earnings per share for the quarter, beating the consensus estimate of -$0.723 by $0.027.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.71.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 63,383,293 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$0.696 in its last earnings report, beating expectations of -$0.723. Following the earnings report the stock price went down -0.664%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
---
Abivax SA Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (323.18% Upside)
$32.50 (323.18% Upside)
Hedge Fund Trend
Decreased
By 619.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.46%
12-Months-Change
Fundamentals
Return on Equity
-171.78%
Trailing 12-Months
Asset Growth
63.36%
Trailing 12-Months
Company Description
Abivax SA Sponsored ADR
Abivax is focused on developing innovative treatments that harness the body¿s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
---
ABVX Stock 12 Month Forecast
Average Price Target
$32.50
▲(323.18% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Neurocrine
―
Regeneron
―
Vertex Pharmaceuticals
―
Best Analysts Covering ABVX
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-18.36%
reiterated a buy rating 22 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -18.36% per trade.
---